

**FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES**

AUGUST 21, 2012

CALL TO ORDER / ANNOUNCEMENTS

The FNLCR Institutional Biosafety Committee was convened at 12:05 p.m. in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 9)

- | | |
|---|---|
| <input checked="" type="checkbox"/> Michael Baseler | <input checked="" type="checkbox"/> Sarah Hooper |
| <input checked="" type="checkbox"/> Theresa Bell | <input type="checkbox"/> Bhargavi Kondragunta (regrets) |
| <input checked="" type="checkbox"/> Rev. David Betzner (left at 1:04pm) | <input type="checkbox"/> Serguei Kozlov (regrets) |
| <input checked="" type="checkbox"/> Stephen Creekmore | <input checked="" type="checkbox"/> Dan McVicar (Chair) |
| <input type="checkbox"/> Bruce Crise (regrets) | <input checked="" type="checkbox"/> Randall Morin |
| <input type="checkbox"/> Eric Freed (regrets) | <input type="checkbox"/> Shalini Oberdoerffer (regrets) |
| <input checked="" type="checkbox"/> Melinda Hollingshead | <input checked="" type="checkbox"/> Raja Sriperumbudur |
| <input checked="" type="checkbox"/> Stephen Hughes (left at 12:55pm) | <input type="checkbox"/> Lucien Winegar (regrets) |

Non-Voting

- Walter Hubert
- Kim DiGiandomenico

Other

Capt. Darrell Laroche
Bruce Tobias

APPROVAL OF MINUTES FROM JULY 17, 2012 MEETING

The minutes from the July 17, 2012 meeting were approved as written. A motion and second were made. (For: 10; Against: 0; Abstain: 0)

ACCIDENT REVIEWS

An animal care worker was bitten by a breeder mouse during one of the cage changes. The mouse was not genetically manipulated. Double gloves were being worn at the time of the incident; however, the employee did not use forceps when picking up the mouse. The employee was treated at the Occupational Health Clinic, reminded to follow proper SOPs and released to work.

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

Andre Nussenzweig 12-63: Over-expression of MLL-AF9 in BM cells for transplantation to assess tumor formation in vivo MLL4 inhibition for therapeutic purposes may be considered for certain types of AML, which is a cancer with high incidence levels among adults. To test this, the lab will: 1) transfect HEK293T cells to produce murine retrovirus particles carrying the MLL-AF9 translocation, 2) infect wild-type or MLL4 deficient BM cells with the particles to stably express the

FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)

INSTITUTIONAL BIOSAFETY COMMITTEE

MINUTES

AUGUST 21, 2012

MLL-AF9 translocation, 3) IV inject the transduced BM cells into sub-lethally irradiated recipient mice, and 4) follow disease progression for 150 days by weekly bleeds (to determine blood counts). During the pre-review there were questions regarding the paperwork and oncogenic nature of the insert being used, but it was clarified prior to full Committee review. The Committee did request, however, that the PI add a statement about complementation with endogenous virus being a greater potential than recombination once the transduced BM cells are inserted into mice. Melinda Hollingshead moved to approve the registry with the aforementioned clarification added to the paperwork. Steve Hughes seconded the motion. For: 10; Against: 0; Abstain: 0

RENEWALS

Wei-Shau Hu 12-58 (07-32): Mechanisms of Retroviral Replication This is a renewal IBC to: study replication of animal viruses such as murine leukemia virus, and known human pathogens such as HIV-1 and HIV-2; manipulate DNA containing viral genomes, transfection of these DNA into cells, harvesting virus, infecting target cells; cell sort lentiviral vector transduced cell pools; conduct biochemical analyses, such as DNA, RNA, and protein analyses, and lastly observe biomolecule behaviors using microscopy including electron microscopy, confocal microscopy, wide-field microscopy, and total internal reflection fluorescence microscopy. During the pre-review there were some concerns regarding how training and competence were conducted; however, the PI adequately addressed these concerns before the registry went to full committee. Dan McVicar motioned to approve the registry with a 'spot check' in the laboratory to verify adherence to the SOP within 6 months and to verify that the space where cell sorting will be conducted will/does adhere to the NIH (draft) Guidelines for Cell Sorters. Theresa Bell seconded the motion. For: 10; Against: 0; Abstain: 0

Stephen Anderson 12-62 (08-03): Analysis of Ly49 and KIR gene Function During NK Cell Development This renewal is to continue studies on the development of natural killer cells and the cell surface receptors that control their ability to kill tumors and virus-infected cells. In order to achieve these aims, it is necessary to evaluate the expression patterns of these receptors, and to produce recombinant DNA constructs containing either mouse or human NK cell receptor genes. Staff will modify genomic DNA to change the activity of promoters or insert a green fluorescent protein (GFP) coding region to track promoter activity in human or mouse cells that have been transfected with recombinant DNA. During full committee review, the committee wanted clarification on where/who the whole blood/serum / blood components were obtained and also strongly recommended the use of shredder columns for shearing the DNA, rather than needles, due to a recent needlestick in the lab. Melinda Hollingshead motioned to approve the registry once the aforementioned were addressed by the PI. Steve Creekmore seconded the motion. For: 10; Against: 0; Abstain: 0

OUTSTANDING ITEMS

Andy Hurwitz 12-60 (08-37) Chronic Prostatitis as a Model for Prostate Carcinogenesis Deferred at July meeting for more comprehensive SOP regarding the use of E. coli 1677; Per request by PI and concurrence with BSO and IBC Chair, response will be provided for review at October 16, 2012 meeting.

FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)

INSTITUTIONAL BIOSAFETY COMMITTEE

MINUTES

AUGUST 21, 2012

Ji Ming Wang 12-30: Use of normal human blood cells for studies of inflammation and cancer in vitro Registry has been deferred since March 2012 meeting. EHS Director was tasked to contact PI with deficiencies found in the laboratory to which the PI responded that the chemotaxis work was suspended due to a change in the research direction and resource constraints. In lieu of this, the IBC still wanted to respond to the observations noted in the July visit by IBC members to his lab. The memo would be revised by the IBC Chair and redistributed to the full committee for review.

AMENDMENTS

Fifteen amendments were processed and approved between the July and August IBC meetings, while five remained outstanding.

OTHER BUSINESS

- Internal Policy: Joint IBC/ACUC/EHS sub-committee for enforcement actions regarding Government employees – tabled to September meeting
- Revisions needed to NCI-Frederick IBC Charter to reflect name change to Frederick National Laboratory (FNL) and scope of research reviewed by the IBC. Revised document to be distributed at September meeting for discussion.

ADJOURNMENT

The meeting adjourned at 1:05pm.

Next meetings:

September 18, 2012

October 16, 2012